Overview of negative progress in drug research in the past month

Based on the statistical data of the Informa database, this article sorted out the progress of the clinical data of drugs under research in the past month (June 16, 2021-July 15, 2021).

According to statistics, within the search time range, the clinical trial data of 8 drugs are not progressing well (Table 1), of which 4 drugs are in clinical phase III, 1 drug is in clinical phase II, and 1 drug is in clinical phase I/ In Phase II, 2 drugs are in the suspension phase

POL6326

POL6326 (Balixafortide) is a CXCR4 inhibitor developed by Polyphor AG

Recently, PolyphorAG announced that POL6326 combined with Eribulin in the treatment of HER2-negative, locally recurring or metastatic breast cancer in the global phase III study (FORTRESS) did not meet the common primary endpoint

The FORTRESS study aimed to evaluate the efficacy, safety and tolerability of intravenous injection of POL6326 combined with Eribulin versus Eribulin as a single agent in the treatment of HER2-negative locally recurrent or metastatic breast cancer

Gosuranemab

Gosuranemab is an antibody developed by Biogen that targets the N-terminus of Tau protein.

In patients with mild cognitive impairment (MCI) due to AD and mild AD, compared with placebo, Gosuranemab did not reach its primary level in the clinical dementia rating scale-box sum (CDR-SB) at week 78 Efficacy endpoint dementia

In the TANGO study, no statistically significant treatment effect was observed for Tau-PET in any dose group at week 78